Conditions: Obesity; Liver Diseases; Liver Fibrosis; Liver Fat; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis; MASLD; MASH; Weight Loss; Insulin Resistance; Insulin Sensitivity; Insulin Sensitivity/Resistance; Metabolic Disease; Diabetes; Diabetes Mellitus, Type 2; NASH With Fibrosis; Non-Alcoholic Fatty Liver Disease; Non Alcoholic Fatty Liver; Non-alcoholic Steatohepatitis
Interventions: Device: ESG + lifestyle modification; Behavioral: Lifestyle modification
Sponsors: Pichamol Jirapinyo, MD, MPH
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
